228 related articles for article (PubMed ID: 29523211)
1. Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year.
Vinod SS; Reed AB; Maxwell J; Cron RQ; Stoll ML
Pediatr Rheumatol Online J; 2018 Mar; 16(1):16. PubMed ID: 29523211
[TBL] [Abstract][Full Text] [Related]
2. Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center.
Koç R; Sönmez HE; Çakan M; Karadağ ŞG; Tanatar A; Çakmak F; Aktay Ayaz N
Rheumatol Int; 2020 May; 40(5):771-776. PubMed ID: 31865444
[TBL] [Abstract][Full Text] [Related]
3. Prevention of acute adverse events related to infliximab infusions in pediatric patients.
Lahdenne P; Wikström AM; Aalto K; Kolho KL
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):785-90. PubMed ID: 20535789
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry.
Choquette D; Faraawi R; Chow A; Rodrigues J; Bensen WJ; Nantel F
J Rheumatol; 2015 Jul; 42(7):1105-11. PubMed ID: 26077415
[TBL] [Abstract][Full Text] [Related]
5. Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years.
Aeschlimann FA; Hofer KD; Cannizzaro Schneider E; Schroeder S; Lauener R; Saurenmann RK
J Rheumatol; 2014 Jul; 41(7):1409-15. PubMed ID: 24833759
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
[TBL] [Abstract][Full Text] [Related]
7. The Safety of Intravenous Cyclophosphamide in the Treatment of Rheumatic Diseases.
Woytala PJ; Morgiel E; Łuczak A; Czesak-Woytala K; Wiland P
Adv Clin Exp Med; 2016; 25(3):479-84. PubMed ID: 27629736
[TBL] [Abstract][Full Text] [Related]
8. The use of infliximab in academic rheumatology practice: an audit of early clinical experience.
Fitzcharles MA; Clayton D; Ménard HA
J Rheumatol; 2002 Dec; 29(12):2525-30. PubMed ID: 12465146
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion.
de Carvalho JF; Dos Santos MNP; de Oliveira JMV; Lanty Silva ANS; de Araujo RPC; Cardozo JB
Adv Rheumatol; 2018 Aug; 58(1):22. PubMed ID: 30657070
[TBL] [Abstract][Full Text] [Related]
10. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
[TBL] [Abstract][Full Text] [Related]
11. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
[TBL] [Abstract][Full Text] [Related]
12. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
[TBL] [Abstract][Full Text] [Related]
13. [Incidence and management of infusion reactions to infliximab in 186 italian patients with rheumatoid arthritis: the Padua experience].
Botsios C; Ostuni P; Todesco S
Reumatismo; 2005; 57(1):44-51. PubMed ID: 15776146
[TBL] [Abstract][Full Text] [Related]
14. Premedication prevents infusion reactions and improves retention rate during infliximab treatment.
Bartoli F; Bruni C; Cometi L; Blagojevic J; Fiori G; Tofani L; Galluccio F; Furst DE; Matucci Cerinic M
Clin Rheumatol; 2016 Nov; 35(11):2841-2845. PubMed ID: 27436188
[TBL] [Abstract][Full Text] [Related]
15. Rapid infliximab infusions in pediatric inflammatory bowel disease.
Yeckes AR; Hoffenberg EJ
J Pediatr Gastroenterol Nutr; 2009 Jul; 49(1):151-4. PubMed ID: 19516188
[TBL] [Abstract][Full Text] [Related]
16. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
Al-Mayouf SM; Alenazi A; AlJasser H
Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
[TBL] [Abstract][Full Text] [Related]
17. Frequency of Severe Infusion Reactions Associated With Outpatient Infusion of Infliximab Without Premedications.
Hutsell SQ; Wu M; Park KT
J Pediatr Gastroenterol Nutr; 2017 Oct; 65(4):430-431. PubMed ID: 28937551
[TBL] [Abstract][Full Text] [Related]
18. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology.
Lequerré T; Vittecoq O; Klemmer N; Goëb V; Pouplin S; Menard JF; Daragon A; Mejjad O; Le Loët X
J Rheumatol; 2006 Jul; 33(7):1307-14. PubMed ID: 16758513
[TBL] [Abstract][Full Text] [Related]
19. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
[TBL] [Abstract][Full Text] [Related]
20. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
